PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.pepgen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/31/2024 | $12.00 | Buy → Neutral | BofA Securities |
| 12/21/2022 | $26.00 | Buy | H.C. Wainwright |
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen's 2024 Inducement Plan as a material inducement to employment to its newly appointed Senior Vice President, Clinical Development, Steve Han, MD, PhD, MMSc. On November 20, 2024, Dr. Han received a non-qualified stock option grant to purchase 95,000 shares of PepGen's common stock, par value $0.0001 per share, with an exercise price of $4.40 per share, the closing price of PepGen's common stock as reported by The N
– FREEDOM-DM1 data from 5 and 10 mg/kg cohorts in patients with DM1 expected in the first quarter of 2025 – – Study designs of CONNECT program optimized based on encouraging results from early cohort – – Strengthened leadership team with addition of Paul Streck, MD, MBA, as head of R&D – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2024. "We are pleased with the progress we have made across our pipeline and organiza
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: Guggenheim's Inaugural Healthcare Innovation Conference (Boston, MA) Monday, November 11, 2024 at 1:00 p.m. ET, Fireside Chat Stifel 2024 Healthcare Conference (New York, NY) Tuesday, November 19, 2024 at 11:30 a.m. ET, Fireside Chat A webcast of each conference presentation will be available on the "Events & Presentations" page within the Investors section of the P
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting a short oral presentation as well as five posters at the 29th Annual Congress of the World Muscle Society (WMS), being held October 8-12, 2024 in Prague, Czech Republic. "We are pleased to be presenting preclinical and clinical data on our Duchenne muscular dystrophy and myotonic dystrophy type 1 programs at this premier global muscle meeting," said James McArthur, PhD, President and CEO of PepGen. "Based on the totality o
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that Christopher Ashton, PhD, intends to retire from the Board of Directors effective September 30, 2024. Dr. Ashton has served on PepGen's Board of Directors since December 2019 and was a member of the audit and compensation committees. "On behalf of the Board of Directors, I would like to thank Chris for nearly five years of service," said Laurie Keating, JD, Chair of PepGen's Board of Directors. "He is our longest serving Director and we will miss his tho
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen's 2024 Inducement Plan as a material inducement to employment to its newly appointed Executive Vice President, Research & Development, Paul D. Streck, M.D., MBA. On August 19, 2024, Dr. Streck received a non-qualified stock option grant to purchase 202,816 shares of PepGen's common stock, par value $0.0001 per share, with an exercise price of $9.83 per share, the closing price of PepGen's common stock as reported
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization. "We are very pleased that Paul is joining PepGen at such an important time for the Company," said James McArthur, Ph.D., President and CEO of PepGen. "Throughout his career, Paul has served in leadership roles across both l
– CONNECT1-EDO51 clinical trial data from low-dose cohort were reported in July. PGN-EDO51 at 5 mg/kg was well tolerated, achieved mean exon skipping levels of 2.15%, mean muscle-adjusted dystrophin production increase of 0.70% from baseline and mean absolute dystrophin production increase of 0.26% from baseline, after three months of dosing – – FREEDOM2-DM1 clinical trial cleared by Health Canada and U.K. Medicines and Healthcare products Regulatory Agency. Initial dosing expected second half of 2024 – – FREEDOM-DM1 clinical results update expected in fourth quarter of 2024 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucle
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of Afsaneh Mohebbi, Ph.D., as Senior Vice President, Portfolio and Program Management and Dave Borah, CFA, as Senior Vice President, Investor Relations and Corporate Communications, effective immediately. "We are thrilled to welcome Afsaneh and Dave to PepGen. The addition of these two senior team members will enhance our expertise in critical areas of the organization, and we eagerly anticipate thei
HC Wainwright & Co. analyst Andrew Fein reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $26 price target.
Wedbush analyst Laura Chico reiterates PepGen (NASDAQ:PEPG) with a Outperform and maintains $20 price target.
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.74) by 14.86 percent.
PepGen (NASDAQ:PEPG) reported quarterly earnings of $0.56 per share.
Gainers PaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ:ALLR) stock increased by 55.84% to $3.58. The company's market cap stands at $1.6 million. HCW Biologics (NASDAQ:HCWB) shares increased by 20.77% to $1.86. The market value of their outstanding shares is at $70.3 million. Portage Biotech (NASDAQ:PRTG) stock rose 17.6% to $0.59. The company's market cap stands at $11.6 million. PepGen (NASDAQ:PEPG) shares rose 16.75% to $14.84. The company's market cap stands at $480.1 million. Akanda (NASDAQ:AKAN) stock increased by 15.82% to $0.17. The
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. GameStop The Trade: GameStop Corp. (NYSE:GME) Director Lawrence Cheng acquired a total of 10,000 shares an average price of $
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 35.3% to $1.38 during Thursday's regular session. The market value of their outstanding shares is at $18.4 million. ZyVersa Therapeutics (NASDAQ:ZVSA) stock increased by 28.74% to $0.99. The company's market cap stands at $4.5 million. Creative Medical Tech (NASDAQ:CELZ) stock increased by 28.18% to $6.1. The market value of their outstanding shares is at $8.4 million. HeartBeam (NASDAQ:BEAT) stock rose 26.53% to $2.05. The company's market cap stands at $53.9 million. Ocean Biomedical (NASDAQ:OCEA) shares increased by 24.4% to $5.03. The market value of their outstanding shares is at $171.3 million. Quantum-Si (NASDAQ:QSI)
4 - PepGen Inc. (0001835597) (Issuer)
3 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
– PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation
BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived
- PGN-EDO51 exhibited the highest levels of oligonucleotide delivery and exon skipping in a clinical study following a single dose when compared to publicly available clinical data for other exon 51 skipping approaches - - PGN-EDO51 was generally well-tolerated - - PepGen plans to initiate a Phase 2a multiple ascending dose (MAD) clinical trial in Duchenne muscular dystrophy (DMD) patients in 1H 2023 - - Data supports the potential of PepGen's Enhanced Delivery Oligonucleotide (EDO) platform in neuromuscular diseases - - Company to host conference call today at 8:00 a.m. ET to discuss these results - BOSTON, Sept. 28, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-sta
BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00
H.C. Wainwright initiated coverage of PepGen with a rating of Buy and set a new price target of $26.00
4/A - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
4 - PepGen Inc. (0001835597) (Issuer)
SC 13G/A - PepGen Inc. (0001835597) (Subject)
SC 13G - PepGen Inc. (0001835597) (Subject)
SC 13G/A - PepGen Inc. (0001835597) (Subject)
SC 13G - PepGen Inc. (0001835597) (Subject)
SC 13G - PepGen Inc. (0001835597) (Subject)
SC 13D/A - PepGen Inc. (0001835597) (Subject)
SC 13G/A - PepGen Inc. (0001835597) (Subject)
SC 13D/A - PepGen Inc. (0001835597) (Subject)
SC 13G/A - PepGen Inc. (0001835597) (Subject)
SC 13G/A - PepGen Inc. (0001835597) (Subject)
10-Q - PepGen Inc. (0001835597) (Filer)
8-K - PepGen Inc. (0001835597) (Filer)
8-K - PepGen Inc. (0001835597) (Filer)
8-K - PepGen Inc. (0001835597) (Filer)
8-K - PepGen Inc. (0001835597) (Filer)
10-Q - PepGen Inc. (0001835597) (Filer)
8-K - PepGen Inc. (0001835597) (Filer)
8-K - PepGen Inc. (0001835597) (Filer)
EFFECT - PepGen Inc. (0001835597) (Filer)
8-K - PepGen Inc. (0001835597) (Filer)
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization. "We are very pleased that Paul is joining PepGen at such an important time for the Company," said James McArthur, Ph.D., President and CEO of PepGen. "Throughout his career, Paul has served in leadership roles across both l
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointments of Afsaneh Mohebbi, Ph.D., as Senior Vice President, Portfolio and Program Management and Dave Borah, CFA, as Senior Vice President, Investor Relations and Corporate Communications, effective immediately. "We are thrilled to welcome Afsaneh and Dave to PepGen. The addition of these two senior team members will enhance our expertise in critical areas of the organization, and we eagerly anticipate thei
BOSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the expansion of its executive team with the appointment of Mary Beth DeLena as General Counsel and Secretary. Ms. DeLena joins PepGen with over 20 years of experience advising global life science companies in a broad range of strategic, transactional, and corporate matters with extensive experience in business development, finance, securities, corporate governance, employment and commercial law. Prior to PepGen, Ma
BOSTON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Howard Mayer, M.D. to the PepGen Board of Directors, effective November 15, 2023. "We are pleased to welcome Dr. Mayer to the PepGen Board," said James McArthur, Ph.D., President and CEO of PepGen. "His extensive clinical development and regulatory experience across a variety of therapeutic areas, including multiple global regulatory filings and approvals in rare diseases, will be invaluable to Pe
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. ("PepGen"), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Habib Joseph Dable to its Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma, and brings nearly three decades of experience working with emerging biotech and big pharma companies. "Habib joins the Board at a pivotal time for PepGen, as we continue to execute our clinical development strategy for PGN-EDO51, our lead candidate in Duchenne muscular dys